MedPath

Efficacy of Melatonin Treatment of Nocturia : a randomized controlled study

Phase 3
Not yet recruiting
Conditions
side effect
Registration Number
TCTR20200317007
Lead Sponsor
Siriraj Routine to research fund
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Female
Target Recruitment
60
Inclusion Criteria

Patients who attend Urogynecology unit, Siriraj Hospital with
-Nocturia patients (>1 times per night)
-Age at least 55 years old
-Welcomed participants

Exclusion Criteria

Patients with
Neurological or psychological abnormalities
History of drug allergy or side effects from melatonin
Hepatic or renal dysfunction
Uncontrolled diabetes mellitus, diabetes insipidus and cardiovascular disease
Currently taking diuretic, tranquillizer, hypnotics or melatonin
Urinary tract infection or tumor
Pelvic organ prolapse at least stage 3
Pelvic organ tumor
Urinary retention
Currently smoking
Taking medication that interact with pharmacokinetics of melatonin including carbamazepine, quinolone, rifampicin, cimetidine, estrogen

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
octurnal urination episode in nocturia patients at 2 weeks after end of taking melatonin or placebo Frequency volume chart
Secondary Outcome Measures
NameTimeMethod
Daytime frequency episode at 2 weeks after end of taking melatonin or placebo Frequency volume chart,Night-time urine volume at 2 weeks after end of taking melatonin or placebo Frequency volume chart,24-hour urine volume at 2 weeks after end of taking melatonin or placebo Frequency volume chart,Maximal voided volume : Daytime and night-time at 2 weeks after end of taking melatonin or placebo Frequency volume chart,Thai version Nocturia Quality of Life Questionnaire score at 2 weeks after end of taking melatonin or placebo Thai version Nocturia Quality of Life Questionnaire,Side effect at 2 weeks after end of taking melatonin or placebo ascertainment
© Copyright 2025. All Rights Reserved by MedPath